Affymax Inc (NASDAQ:AFFY) jumped up 10.13% to $13.16. Affymax and Takeda Pharmaceuticals announced supply agreement for Omontys injection with Fresenius Medical Care North America. Takeda Pharmaceuticals America Inc has entered into a supply agreement for sourcing and supply of Omontys injection to Fresenius Medical Care North America and certain of its affiliates. Omontys is the only per monthly erythropoiesis-stimulating agent for anemia available to the dialysis patient population with chronic kidney disease in the United States. Affymax Inc announced the promotion of Michael Holfinger, Ph.D. to vice president, manufacturing and CMC development.
TearLab Corporation (USA) (NASDAQ:TEAR) soared 6.09% to $3.32 on a traded volume of 121k shares. The stock opened at $3.15. The 52-week range of the stock $0.78 and $4.88.The Company has Price/Sales ratio of 46.19 and Price/Book ratio of 28.72. The 50-Day Moving Average and 200-Day Moving Average prices is $3.11 and $2.79 respectively.
VirnetX Holding Corporation (NYSEAMEX: VHC) moved up 4.54% to $37.50. VirnetX Holding Corp and Mitel Networks Corporation signed a patent license agreement. Under the terms of the agreement, VirnetX has agreed to license certain of its patents to Mitel. This is for a one-time payment to VirnetX and an ongoing reasonable royalty for all future sales through the expiration of the licensed patents as outlined in the agreement with respect to certain current and future IP-encrypted products.
Merck & Co Inc (NYSE:MRK) escalated 4.20% to $42.94 on a thickly traded volume of 18.66 million shares. According to report from Reuters, the Company’s experimental osteoporosis drug odanacatib has shown that it reduces fracture risk, prompting outside monitors to recommend that the study be stopped early. The company said it expects to take a number of months to wind up the trial. Merck expects to submit regulatory applications for U.S., European and Japanese approval of odanacatib in the first half of next year.
EnteroMedics Inc (NASDAQ:ETRM) increased 6.29% to $3.89 on a traded volume of 274k shares. The Company announced that Greg S. Lea, SVP and Chief Financial Officer scheduled to present at the 7th Annual JMP Securities Healthcare Conference on July 13, 2012 in New York, NY. Mr. Lea will provide an overview of the Company and an update on its VBLOC vagal blocking therapy development and commercialization program.